0HOH.L - bluebird bio, Inc.
LSE - LSE Prezzo differito. Valuta in USD.
Al 03:16PM BST. Mercato aperto.
Il grafico dei titoli non è supportato dal tuo browser attuale
| Chiusura precedente | 3,5413 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 10.470 |
| Capitalizzazione | 2,055M |
| Beta (5 anni mensile) | 0,93 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -10,4290 |
| Prossima data utili | 02 ago 2023 - 07 ago 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireReal Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy
The risk-sharing agreement removes economic uncertainties, enabling regional and mid-sized health plans to provide patients with transfusion-dependent beta-thalassemia access to ZYNTEGLOFLORHAM PARK, N.J., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Real Endpoints, the leading market-access platform and advisory firm, announced a collaboration with bluebird bio, inc. (Nasdaq: BLUE), to provide multiple health plans with access to an innovative, outcomes-based agreement for ZYNTEGLO® (betibeglogene autotem